Arcus Biosciences, Inc. (RCUS) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
3928 POINT EDEN WAY HAYWARD, CA 94545 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in millions)Annual | Quarterly
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 499 | 173 | 58 | 71 | ||
| Cash and cash equivalents | 148 | 173 | 58 | 71 | ||
| Short-term investments | 351 | |||||
| Receivables | 2 | 2 | 0 | |||
| Contract with customer, asset | 745 | 1 | 0 | |||
| Other undisclosed current assets | 16 | 560 | 135 | 188 | ||
| Total current assets: | 1,262 | 736 | 193 | 259 | ||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 105 | 13 | ✕ | |||
| Property, plant and equipment | 32 | 11 | 9 | 11 | ||
| Long-term investments and receivables | 182 | 6 | 1 | |||
| Long-term investments | 182 | 6 | 1 | |||
| Restricted cash and investments | 3 | 0 | 0 | 0 | ||
| Other noncurrent assets | 8 | 6 | 1 | 0 | ||
| Other undisclosed noncurrent assets | 3 | |||||
| Total noncurrent assets: | 330 | 36 | 10 | 16 | ||
| TOTAL ASSETS: | 1,592 | 772 | 203 | 275 | ||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 53 | 34 | 14 | 9 | ||
| Accounts payable | 10 | 16 | 5 | 3 | ||
| Accrued liabilities | 24 | 10 | 10 | 6 | ||
| Employee-related liabilities | 17 | 9 | ||||
| Taxes payable | 2 | |||||
| Deferred revenue | 102 | 75 | 7 | ✕ | ||
| Other liabilities | 0 | 4 | 1 | 2 | ||
| Other undisclosed current liabilities | 11 | 10 | 6 | |||
| Total current liabilities: | 166 | 122 | 23 | 17 | ||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 117 | 15 | ||||
| Operating lease, liability | 117 | 15 | ✕ | |||
| Liabilities, other than long-term debt | 467 | 133 | 17 | 6 | ||
| Deferred revenue | 462 | 123 | 12 | ✕ | ||
| Deferred rent credit | 4 | 4 | ||||
| Other liabilities | 5 | 10 | 1 | 2 | ||
| Other undisclosed noncurrent liabilities | 17 | |||||
| Total noncurrent liabilities: | 584 | 148 | 17 | 23 | ||
| Total liabilities: | 750 | 270 | 39 | 40 | ||
| Stockholders' equity | ||||||
| Stockholders' equity attributable to parent | 841 | 502 | 164 | 235 | ||
| Common stock | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 1,118 | 830 | 369 | 358 | ||
| Accumulated other comprehensive income (loss) | (1) | 0 | 0 | (0) | ||
| Accumulated deficit | (275) | (328) | (205) | (123) | ||
| Total stockholders' equity: | 841 | 502 | 164 | 235 | ||
| TOTAL LIABILITIES AND EQUITY: | 1,592 | 772 | 203 | 275 | ||
Income Statement (P&L) ($ in millions) Annual | Quarterly
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|
| Revenues | 383 | 78 | 15 | 8 | |
| Gross profit: | 383 | 78 | 15 | 8 | |
| Operating expenses | (329) | (202) | (104) | (63) | |
| Operating income (loss): | 54 | (124) | (89) | (55) | |
| Nonoperating income | 0 | 1 | 4 | 5 | |
| Income (loss) from continuing operations before equity method investments, income taxes: | 55 | (123) | (85) | (50) | |
| Loss from equity method investments | (1) | ||||
| Income (loss) from continuing operations before income taxes: | 55 | (123) | (85) | (50) | |
| Income tax expense | (2) | ||||
| Income (loss) before gain (loss) on sale of properties: | 53 | (123) | (85) | (50) | |
| Other undisclosed net income | 1 | ||||
| Net income (loss) available to common stockholders, diluted: | 53 | (123) | (85) | (50) | |
Comprehensive Income ($ in millions)Annual | Quarterly
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|
| Net income (loss): | 53 | (123) | (85) | (50) | |
| Other comprehensive income (loss) | (1) | (0) | 0 | (0) | |
| Comprehensive income (loss), net of tax, attributable to parent: | 52 | (123) | (85) | (50) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.